Bio-Rad Laboratories (BIO) Earning Somewhat Favorable News Coverage, Study Finds

Media stories about Bio-Rad Laboratories (NYSE:BIO) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bio-Rad Laboratories earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 46.9298845587063 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Bio-Rad Laboratories stock traded down $3.37 during mid-day trading on Friday, hitting $244.10. The company’s stock had a trading volume of 127,070 shares, compared to its average volume of 165,748. The company has a market capitalization of $7,456.23, a PE ratio of 59.54, a price-to-earnings-growth ratio of 2.14 and a beta of 0.94. The company has a quick ratio of 2.75, a current ratio of 3.93 and a debt-to-equity ratio of 0.15. Bio-Rad Laboratories has a one year low of $199.94 and a one year high of $279.59.

How to Become a New Pot Stock Millionaire

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.28 by $0.22. The company had revenue of $620.43 million for the quarter, compared to the consensus estimate of $618.89 million. Bio-Rad Laboratories had a return on equity of 3.63% and a net margin of 5.31%. research analysts anticipate that Bio-Rad Laboratories will post 5.86 earnings per share for the current year.

BIO has been the topic of several recent research reports. Wells Fargo increased their price target on Bio-Rad Laboratories from $280.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, March 20th. Citigroup increased their price target on Bio-Rad Laboratories to $325.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. CL King lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a report on Friday, February 16th. ValuEngine upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Monday. Finally, Jefferies Group increased their price target on Bio-Rad Laboratories to $325.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $297.20.

TRADEMARK VIOLATION NOTICE: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3336562/bio-rad-laboratories-bio-earning-somewhat-favorable-news-coverage-study-finds.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Insider Buying and Selling by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Decentralized Universal Basic Income Price Reaches $123.81 on Exchanges
Decentralized Universal Basic Income Price Reaches $123.81 on Exchanges
Quark Trading Up 30.6% Over Last 7 Days
Quark Trading Up 30.6% Over Last 7 Days
Electronic PK Chain  24-Hour Volume Hits $832,169.00
Electronic PK Chain 24-Hour Volume Hits $832,169.00
Berenberg Bank Initiates Coverage on Ironwood Pharmaceuticals
Berenberg Bank Initiates Coverage on Ironwood Pharmaceuticals
DRP Utility  Price Reaches $0.35
DRP Utility Price Reaches $0.35
GCN Coin  Price Down 4.7% Over Last Week
GCN Coin Price Down 4.7% Over Last Week


Leave a Reply

© 2006-2018 Ticker Report. Google+.